跳至主要内容
临床试验/NCT00086372
NCT00086372
已完成
不适用

Acute HIV Infection and Early Disease Research Program (AIEDRP) CORE01 Database

National Institute of Allergy and Infectious Diseases (NIAID)30 个研究点 分布在 5 个国家目标入组 157 人2003年7月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
HIV Infections
发起方
National Institute of Allergy and Infectious Diseases (NIAID)
入组人数
157
试验地点
30
状态
已完成
最后更新
13年前

概览

简要总结

This is a long-term follow-up study of people who are identified during acute or recent HIV infection and are being followed at clinical research sites associated with the Acute HIV Infection and Early Disease Research Program (AIEDRP).

详细描述

AIEDRP was established to develop and evaluate data from studies of patients with acute or recent HIV infection. Long-term effects of antiretroviral therapies raise questions regarding the value and necessity of therapeutic interventions during acute and early HIV infection. Conventional randomized clinical trials are generally designed with finite endpoints; most patients who reach an endpoint or complete a protocol are no longer followed. As a result, long-term virologic, immunologic, and clinical outcome data are not available. This is particularly true for participants who fail therapy, require changes in treatment, or develop a treatment-limiting toxicity in a time-limited study. This database study will establish a cohort of HIV infected individuals who are participating in HIV studies at AIEDRP sites and of HIV infected individuals who have chosen to defer therapy but agree to be followed by this study. The study will facilitate longitudinal and prospectively planned meta-analyses or cross-protocol analyses of AIEDRP studies by developing data collection guidelines, defining common research goals, and creating data templates. The primary aim is to determine the long-term virologic, immunologic, and clinical outcomes and complications for patients who were diagnosed during acute or early HIV infection. Participants in this study will be followed for at least 5 years. Study visits will occur at Weeks 2, 4, and 12, and then every 12 weeks thereafter, through Week 96. After 2 years, study visits will occur every 24 weeks until the end of the study. Participants who start antiretroviral therapy at or after Week 2 will restart the study visit schedule. Study visits will include a medical interview, adherence questionnaire, and blood tests. Duplicate tests performed as part of another study will not be performed if the results of those tests are available.

注册库
clinicaltrials.gov
开始日期
2003年7月
结束日期
2007年4月
最后更新
13年前
研究类型
Observational
性别
All

研究者

入排标准

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

未指定

研究点 (30)

Loading locations...

相似试验